Anti-Ganglioside Dot 12 LINE en CIDP

Intro tekst

Het gebruik van Anti-Ganglioside Dot 12 LINE - Profile Diagnostics (IgG/IgM) is nu beschreven door NeuroCure in een recente publicatie waarin deze innovatieve multiplex line-immunoassay een verhoogde frequentie aantoonde van anti-gangliosiden IgM in chronische ontstekings demyeliniserende polyneuropathie (CIDP) patiënten. Anti-sulfatide werd geassocieerd met immune-mediated fenotypen en samen met anti-GM1 en anti-GM2 geassocieerd met jongere leeftijd. 

[Klehmet J. et al., Clin Chem Lab Med 2018].

Afbeelding
Juliane Klehmet*, Stefanie Märschenz, Klemens Ruprecht, Benjamin Wunderlich, Thomas Büttner, Rico Hiemann, Dirk Roggenbuck and Andreas Meisel

Analysis of anti-ganglioside antibodies by a line immunoassay in patients with chronic-inflammatory demyelinating polyneuropathies (CIDP)

The novel multiplex semi-quantitative line immunoassay using 11 different gangliosides (GM1, GM2, GM3, GM4, GD1a, GD1b, GD2, GD3, GT1a, GT1b and GQ1b) and SF was used to analyze anti-ganglioside autoantibody (aGAAb) profiles and revealed an elevated frequency of at least one aGAAb IgM in chronic-inflammatory demyelinating polyneuropathy(CIDP)/multifocal motor
neuropathy (MMN) patients. Anti-SF, aGM1 and aGM2 IgM were associated with younger age and anti-SF with immune-mediated neuropathies (IN) phenotypes.

https://doi.org/10.1515/cclm-2017-0792

 

Download hier de productinformatie brochure